CO2 Advancing the Methods of Cost-Effectiveness Analysis: Why It's Time to Move on from ICERs and Thresholds  by Paulden, M.
PODIUM SESSION I:
NEW CONCEPTS FOR HEALTH CARE DECISION MAKING
CO1
INDIVIDUAL DECISIONS AND SOCIAL VALUE: A CONCEPTUAL FRAMEWORK TO
EXPLORE ALTERNATIVE DECISION MAKING APPROACHES AND THE VALUE OF
HETEROGENEITY IN THE ERA OF INDIVIDUALIZED CARE
Espinoza MA, Manca A, Sculpher MJ, Claxton K
University of York, Heslington, York, UK
The value of understanding and incorporating heterogeneity in decisions based on
cost-effectiveness has been matter of growing interest in healthcare. Recent con-
tributions have been proposed to characterize this value. They include the ex-
pected value of individualized care (EVIC) and the static and dynamic value of
heterogeneity (VoH). While the EVIC represents the expected societal cost of ignor-
ing patient-level heterogeneity, the VoH approach helps to define the optimal spec-
ification of a subgroup for cost-effectiveness analysis considering the available
information and the related parameter uncertainty. However, the interpretation of
such metrics should consider additional elements of the health system. Social
value judgments and the fact that individuals do not necessarily make decisions
according to social interests should be taken into account when the healthcare
system pursues to implement a centered patient model such as individualized
care. This paper develops a conceptual framework to explore the impact of alter-
native approaches to decision-making on population health and the potential
trade-offs between those approaches. The main purpose of the study is to make
explicit considerations that could help policymakers in their task of evaluating the
implementation of a centered patient model in a healthcare system. Four decision
making approaches are defined on the basis of two elements: first, the type of
values used to construct health outcomes (private or societal values) and second,
the level at which a decisions is made (central versus devolved). The model is
formalized using classical cost-effectiveness decision rules. The alternative ap-
proaches are contrasted in terms of net health benefits which are estimated for
different scenarios and illustrated with a stylized numerical example.
CO2
ADVANCING THE METHODS OF COST-EFFECTIVENESS ANALYSIS: WHY IT’S
TIME TO MOVE ON FROM ICERS AND THRESHOLDS
Paulden M
University of Toronto, Toronto, ON, Canada
OBJECTIVES: Cost-effectiveness analysis of health technologies typically involves
the calculation of incremental cost-effectiveness ratios (ICERs). In some jurisdic-
tions, decision makers compare these ICERs to an explicit cost-effectiveness
“threshold” as part of their deliberations. The use of a threshold remains con-
troversial and there is disagreement over what such a threshold, if adopted,
should represent. Furthermore, there are many issues and limitations with the
interpretation of ICERs. This paper argues that the needs of decisionmakers and
patients would be better served by abandoning ICERs and thresholds altogether
and adopting instead a decision framework based upon a modified notion of
“net benefit”. METHODS: Using recent Ontario-based cost-effectiveness analyses
as examples, we demonstrate that the traditional interpretation of ICERs can be
misleading. We also demonstrate why comparing ICERs to an explicit threshold
cannot satisfy the needs of decisionmakers or patients – regardless of the thresh-
old used – except under very specific circumstances. We then show how the
traditional “net benefit” approach to decision making may be modified to incor-
porate concerns for efficiency, equity, societal and ethical values, and patient
preferences. CONCLUSIONS: Abandoning ICERs and thresholds and adopting a
decision framework based upon a modified notion of “net benefit” would not only
address many of the issues with ICERs and thresholds but would be easier for
decision makers to interpret. It would also allow decision makers who adopt mul-
tiple decision making criteria (such as concerns for efficiency, equity, societal and
ethical values, and patient preferences) to make explicit trade offs between these
criteria.
CO3
MINIMIZING THE COSTS OF ANALYZING THE VALUE OF HEALTH RESEARCH
Hoomans T, Seidenfeld J, Meltzer D
University of Chicago, Chicago, IL, USA
Value-of-information (VOI) analysis can establish the expected benefits from
health research. This typically involves themodeling of a disease and its treatment
to fully characterize the uncertainty in outcomes of the interventions under study,
which is generally complex and costly. As such, full modeling VOI often limits the
practical use of VOI in prioritizing and designing research studies, particularly
low-cost studies. This study 1) identifies approaches that canminimize the costs of
performing VOI analysis; and 2) describes an algorithm for selecting the best VOI
approach for a given clinical question. As alternatives to full modeling VOI, we
identified conceptual VOI, minimal modeling and maximal modeling to be lower-
cost approaches to VOI. In conceptual VOI, information is used about each of the
multiplicative elements of VOI, including the durability of research evidence, to
provide informative bounds on VOI without formally quantifying this through
modeling. When data on comprehensive outcome measures, like QALYs or net
benefit, are readily available from existing research, it may be possible to perform
VOI with only minimal modeling. Instead of constructing separate models, a max-
imal modeling VOI uses a single comprehensive model to simultaneously inform
multiple clinical questions. To select the best approach to VOI, our algorithm be-
gins with conceptual VOI, followed by the clustering of clinical questions andmax-
imal modeling VOI, and then minimal modeling using comprehensive outcomes.
In applying the algorithm to informpriority-setting for systematic reviewswithin a
U.S.-based agency, we found the algorithm useful and found practical applications
for each of the lower-cost VOI approaches. Although full modeling VOI may aid in
the planning and design of research, we find limited conditions for its use in pri-
oritizing low-cost studies. We conclude that VOI may be useful in research prior-
ization and design, especially because methodology exists that can minimize the
costs of analyzing the value of health research.
CO4
COST-EFFECTIVENESS ANALYSIS - APPROPRIATE FOR ALL SITUATIONS?
Standaert B1, Ethgen O2, Emerson RA3
1GlaxoSmithKline Biologicals, Wavre, Belgium, 2University of Liege, Liege, Belgium, 3Emerson
Consulting, Tervuren, Belgium
Cost-effectiveness analysis (CEA) is routinely proposed to inform decisionmaking,
where a new intervention is evaluated against standard of care and the incremen-
tal investment per effect is compared against a threshold. In CEA one can explore
the relationship between the incremental cost-effectiveness ratio (ICER) and the
price of a new intervention. The ICER will depend upon the cost-difference in the
numerator, subject to healthcare system investment; and effects difference in the
denominator, again dependent upon existing investment and remaining disease
burden. The gradient of the plot between ICER (y-axis) and Price (x-axis) can be
informative to the possible usefulness of CEA. Firstly consider a new intervention
with little health-gain in a rich healthcare setting such as end-of-life interventions
in a developed country. The plot gradient will be approaching vertical, the ICER
being very sensitive to price due to the relatively small denominator. We would
argue CEA adds little value to decision makers, the decision relates to affordability
for perceived unmet need. If effects are equivalent between interventions, cost-
minimization analysis could be appropriate. Secondly consider a new intervention
with significant health-gain in a poor healthcare setting with little scope for cost-
offsets. The plot gradient will be approaching horizontal, the ICER being relatively
insensitive to price due to the large denominator. Again we would argue CEA may
add little value to decisionmakers.Wheremultiple interventions could be contem-
plated, even if all are cost-effective each would require investment; therefore op-
timization of possible budget across interventions to maximize health-gain would
be more useful. We conclude the gradient of the ICER to Price relationship could
indicate the usefulness of CEA to decision makers. In situations where the ICER
compared with a threshold is highly sensitive or highly insensitive to price, alter-
native methods could be more useful to help prioritize implementation of new
interventions.
PODIUM SESSION I:
MEDICARE POLICIES & HEALTH CARE
ME1
EFFECT OF MEDICARE PART D ON DRUG UTILIZATION, DRUG EXPENDITURES,
AND HEALTH CARE SPENDING IN PATIENTS WITH CHRONIC PULMONARY
OBSTRUCTIVE DISEASE
Cheng LI, Rascati KL
The University of Texas at Austin, Austin, TX, USA OBJECTIVES: To evaluate the impact of
Medicare Part D on drug utilization, drug expenditures, and healthcare expendi-
tures in patients with chronic pulmonary obstructive disease (COPD). METHODS:
This was a retrospective study using a national sample of 688 Medicare-eligible
beneficiaries with COPD from the pooled Medical Expenditure Panel Survey 2005-
2009 data. Quantile regression was used to estimate the following outcomes: 1)
number of prescription fills; 2) total drug expenditures; 3) out-of-pocket (OOP) drug
expenditures; 4) Medicare-paid drug expenditures; 5) total health care expendi-
tures (including all payments for inpatient care, outpatient care, prescription
drugs, and other medical services); 6) OOP health care expenditures; and 7) Medi-
care-paid healthcare expenditures. For each outcome variable, the 50th, 75th, and
95th percentiles were estimated, adjusting for demographics and comorbidity. All
expenditures were inflation-adjusted to 2009 dollars. RESULTS: From 2005 to 2009,
the median annual number of prescription fills increased by 8.2 (29.6%), although
not statistically significant (P0.118). Total drug expenditures did not change sig-
nificantly; however, quantile regressions showed reductions in OOP drug expendi-
tures across the 50th (-$227 [-36.0%], P0.024), 75th (-$738 [-50.8%], P0.017), and
90th (-$1,639 [-58.5%], P0.001) percentiles, as well as increases in Medicare-paid
drug expenditures across the 50th ($624 [310.0%], P00.001), 75th ($1,774 [183.0%],
P0.001), and 90th ($2,023 [80.2%], P0.004) percentiles, adjusting for the covari-
ates. Total and Medicare-paid health care expenditures did not change signifi-
cantly between 2005 and 2009. OOP health care expenditures decreased at the 90th
percentile (-$3,219 [-56.2%], P0.003), but not at the median or 75th percentile.
CONCLUSIONS: Medicare Part D had shifted the costs for prescription drugs from
patients to Medicare in a nationally representative sample of Medicare-eligible
beneficiaries with COPD. Part D was not associated with significant differences in
drug utilization, total drug spending or total health care expenditures.
ME2
EFFECT OF MEDICARE PRESCRIPTION DRUG PROGRAM (PART D) ON
MEDICATION ADHERENCE FOR DUAL ELIGIBLES: CASE OF ACEIS AND ARBS
Kim JA, Park T
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: The prescription drug coverage for dual eligibles, beneficiaries for
both Medicaid and Medicare, was moved from Medicaid to Medicare Prescription
Drug (Part D) program in 2006. Adherence to antihypertensive has been reported as
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